trending Market Intelligence /marketintelligence/en/news-insights/trending/Q0biMXJFoOsiDZxm45iVFg2 content esgSubNav
In This List

Soleno plans joint venture with OptAsia; directors resign

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Soleno plans joint venture with OptAsia; directors resign

Soleno Therapeutics Inc. and its unit Capnia Inc. plan to form a joint venture with Hong Kong-based OptAsia Healthcare Ltd. for the development and commercialization of the Sensalyze technology.

Capnia's Sensalyze technology includes the CoSense end-tidal carbon monoxide monitor that assists in the detection of excessive hemolysis in neonates.

According to the agreement, OptAsia will invest up to $2.2 million in tranches to buy shares of Capnia, which will no longer remain Soleno's unit as a result of the investment.

In addition, OptAsia has the option to buy the remaining shares of Capnia at a prespecified future time, and at a value based on revenue.

OptAsia will also pay $40,000 for the exclusive right, title and interest to acquire the CoSense technology.

The transaction narrows Soleno's business solely on the development of rare disease therapeutics. As a result of this shift in focus, the company said Stephen Kirnon, Edgar Engleman and Steinar Engelsen will step down from the company's board on Dec. 31.